Format

Send to

Choose Destination
Rheumatology (Oxford). 2018 Apr 1;57(4):591-593. doi: 10.1093/rheumatology/kex016.

How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?

Author information

1
Amsterdam Rheumatology and Immunology Center, Academic Medical Center (AMC)/University of Amsterdam, The Netherlands.
PMID:
28339729
DOI:
10.1093/rheumatology/kex016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center